Table IV.

Univariable and multivariable competing risk analysis for POD within 60 months in the patient group aged >75 (n=356)

Characteristics	Univariable model		Multivariable model
	SHR [95% CI]	p-value	SHR [95% CI]	p-value
Sex
Men	1 (reference)
Women	0.72 [0.39–1.33]	0.296
Immunosuppression
Yes	0.93 [0.34–2.51]	0.884
No	1 (reference)
Comorbiditiesa
None	1 (reference)
Mild	0.58 [0.24–1.43]	0.239
Moderate	0.93 [0.42–2.06]	0.867
Severe	1.38 [0.55–3.46]	0.498
Tumour diameter
< 20 mm	1 (reference)		1 (reference)
20–39 mm	2.77 [1.54–4.99]	0.001	1.16 [0.51–2.65]	0.721
≥ 40 mm	4.17 [1.79–9.72]	0.001	2.90 [1.08–7.76]	0.034
Tumour differentiation
Well	1 (reference)		1 (reference)
Moderate	2.50 [1.23–5.11]	0.012	3.38 [1.34–8.57]	0.010
Poor	5.28 [2.28–12.21]	< 0.001	6.72 [2.39–18.92]	< 0.001
Invasion depth
< 2 mm	1 (reference)		1 (reference)
2–6 mm	3.31 [1.46–7.49]	0.004	3.22 [1.11–9.35]	0.032
> 6 mm	9.25 [3.82–22.43]	< 0.001	7.39 [2.16–25.25]	0.001
Perineural invasion
Yes	3.13 [1.66–5.91]	< 0.001	1.31 [0.60–2.85]	0.501
No	1 (reference)		1 (reference)
Vascular invasion
Yes	1.65 [0.38–7.18]	0.504
No	1 (reference)
Surgical margin
< 2 mm	1 (reference)		1 (reference)
≥ 2 mm	0.44 [0.23–0.85]	0.014	0.79 [0.41–1.52]	0.472

^aComorbidities were indexed by the Adult Comorbidity Evaluation-27 (ACE-27). 95% CI: 95% confidence interval; POD: progression of disease, comprising local recurrence, nodal metastasis and distant metastasis; SHR: subhazard ratio.

Significant p-values are shown in bold.